Detection and Outcome of Endocervical Atypia in Cytology in Primary HPV Screening Programme.
HPV
adenocarcinoma in situ
atypical endocervical cells
cytology
endocervical adenocarcinoma
screening
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
20 Dec 2021
20 Dec 2021
Historique:
received:
22
11
2021
revised:
06
12
2021
accepted:
08
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Most endocervical adenocarcinomas (EAC) are associated with high-risk HPV (hrHPV) infection, with HPV genotypes 16, 18 and 45 accounting for >90% of the cases. Among endocervical glandular lesions, screening with hrHPV test has previously shown to predict the outcome better than cytology, although around one-fifth of the EAC remain negative both in hrHPV testing and cytology. The study consists of two consecutive HPV-primary screening rounds, conducted in 2012-2015 and 2017-2020. Of the 87 women aged 35 to 60 years of age diagnosed with Atypical endocervical cells, NOS or Atypical endocervical cells, favor neoplastic cytology during the first screening round, 63 (72.4%) were hrHPV positive and 24 (27.6%) were hrHPV negative. Among hrHPV positive patients, three EAC, two adenocarcinomas in situ (AIS), one AIS + high-grade intraepithelial lesion (HSIL) and 13 HSIL were found. Of the histologically verified lesions, 68.4% (13/19) were purely of squamous origin. All the EAC and AIS were HPV16 or HPV 18 positive. No high-grade histological lesions were found among the hrHPV negative patients with cytological glandular atypia. A later database search revealed one HPV-negative, gastric-type mucinous EAC that was missed by the HPV primary screening.
Identifiants
pubmed: 34943636
pii: diagnostics11122402
doi: 10.3390/diagnostics11122402
pmc: PMC8700048
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Competitive Research Funding of the Pirkanmaa Hospital District
ID : X5211
Références
J Natl Cancer Inst. 2018 May 1;110(5):501-508
pubmed: 29145648
Diagn Cytopathol. 2016 May;44(5):389-93
pubmed: 26878832
JAMA. 2018 Jul 3;320(1):43-52
pubmed: 29971397
Acta Cytol. 2017;61(4-5):359-372
pubmed: 28693017
N Engl J Med. 2007 Oct 18;357(16):1589-97
pubmed: 17942872
Mod Pathol. 2014 Dec;27(12):1559-67
pubmed: 24762548
Cytopathology. 2009 Dec;20(6):351-8
pubmed: 18522633
Diagn Cytopathol. 2008 Apr;36(4):270-4
pubmed: 18335557
Lancet Oncol. 2010 Mar;11(3):249-57
pubmed: 20089449
Br J Cancer. 2019 May;120(10):1015-1022
pubmed: 30988395
Eur J Cancer. 2015 May;51(8):950-68
pubmed: 25817010
Diagn Cytopathol. 1995 Oct;13(3):202-8
pubmed: 8575278
Diagnostics (Basel). 2021 Mar 30;11(4):
pubmed: 33808260
Lancet Oncol. 2011 Jul;12(7):663-72
pubmed: 21684207
APMIS. 2019 Nov;127(11):710-716
pubmed: 31403733
Cancer Cytopathol. 2016 Aug;124(8):589-95
pubmed: 27115423
Int J Cancer. 2016 Jan 15;138(2):409-16
pubmed: 26334557
Am J Clin Pathol. 2002 Jan;117(1):96-102
pubmed: 11789738
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Gynecol Oncol. 2015 Feb;136(2):189-97
pubmed: 25579108
Acta Cytol. 1999 May-Jun;43(3):351-6
pubmed: 10349361
Int J Gynecol Pathol. 1993 Jul;12(3):208-18
pubmed: 8344758
Acta Obstet Gynecol Scand. 2016 Nov;95(11):1220-1227
pubmed: 27591407
Acta Obstet Gynecol Scand. 2021 Mar;100(3):403-409
pubmed: 33037625
Diagn Cytopathol. 2017 Oct;45(10):867-872
pubmed: 28771986
Cancer. 2008 Aug 25;114(4):236-41
pubmed: 18548530
Diagnostics (Basel). 2021 Aug 05;11(8):
pubmed: 34441354
Lancet Oncol. 2012 Jan;13(1):78-88
pubmed: 22177579
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Cytopathology. 2008 Feb;19(1):34-43
pubmed: 18205627
Health Technol Assess. 2009 Nov;13(51):1-150, iii-iv
pubmed: 19891902
Cytopathology. 2019 Mar;30(2):150-156
pubmed: 30421573